Think of Lancora as a Niche Drug for Heart Failure

Lancora (LAHN-core-ah, ivabradine) will be a new option for treating systolic heart failure. It's marketed as Corlanor in the U.S.

It works by inhibiting the If or "funny" current in the heart. This lowers heart rate...withOUT causing a drop in blood pressure.

Ivabradine prevents one in 25 patients from being hospitalized over 2 years...when ADDED to an ACEI or ARB, beta-blocker, and aldosterone antagonist. But it DOESN'T reduce overall mortality.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote